Elanco Animal Health ELAN
$25.74 −$0.55 (-2.09%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $25.22 -2.04%
Open$26.22
Prev close$26.29
Day range$25.58 – $26.93
Volume5.83M
Market cap$12.87B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$1.27B+11.3% YoY
Operating profit$84.00M+211.1% YoY
Net profit$18.00M+152.9% YoY
Diluted EPS$0.04+157.1% YoY
Free cash flow$156.00M+22.8% YoY
Operating cash flow$216.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin56.2%
Operating margin7.6%
Net margin-2.9%
Return on equity-2.2%
Return on assets-1.1%
Return on invested capital0.1%
Current ratio2.09
Liabilities / assets50.3%
Cash & investments$465.00M
Total debt$3.71B
Net cash (debt)-$3.24B
Free cash flow / sales7.9%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $1.27B | $1.37B | $1.37B | $4.72B | $1.14B |
| Total Operating Revenue | $1.27B | $1.37B | $1.37B | $4.72B | $1.14B |
| Cost of Revenue | $545.00M | $570.00M | $586.00M | $2.12B | $555.00M |
| Gross Profit | $720.00M | $798.00M | $785.00M | $2.59B | $589.00M |
| Operating Expense | $636.00M | $680.00M | $616.00M | $2.34B | $570.00M |
| Selling and Admin Expenses | $393.00M | $449.00M | $381.00M | $1.43B | $338.00M |
| Research & Development | $99.00M | $92.00M | $97.00M | $368.00M | $93.00M |
| Depreciation & Amortization & Depletion | $144.00M | $139.00M | $138.00M | $543.00M | $139.00M |
| -Depreciation & Amortization | $144.00M | $139.00M | $138.00M | $543.00M | $139.00M |
| Operating Profit | $84.00M | $118.00M | $169.00M | $252.00M | $19.00M |
| Net Non-Operating Interest Income (Expense) | -$59.00M | -$59.00M | -$57.00M | -$220.00M | -$80.00M |
| Non-Operating Interest Expense | $59.00M | $59.00M | $57.00M | $220.00M | $80.00M |
| Other Income (Expense) | -$1.00M | -$3.00M | -$25.00M | -$256.00M | -$198.00M |
| Special Income (Charges) | -$3.00M | -$9.00M | -$16.00M | -$237.00M | -$202.00M |
| -Less:Restructuring and Mergern & Acquisition | $3.00M | $5.00M | $14.00M | $119.00M | $116.00M |
| -Less:Impairment of Capital Assets | $0.00 | – | – | $71.00M | $47.00M |
| Other Non-Operating Income (Expenses) | $2.00M | $6.00M | -$9.00M | -$19.00M | $4.00M |
| Pretax Profit | $24.00M | $56.00M | $87.00M | -$224.00M | -$259.00M |
| Tax | $6.00M | $2.00M | $30.00M | $8.00M | $17.00M |
| Net Profit | $18.00M | $54.00M | $57.00M | -$232.00M | -$276.00M |
| Profit from Continuing Operations | $18.00M | $54.00M | $57.00M | -$232.00M | -$276.00M |
| Net Income to Parent Company | $18.00M | $54.00M | $57.00M | -$232.00M | -$276.00M |
| Net Income to Common Stockholders | $18.00M | $54.00M | $57.00M | -$232.00M | -$276.00M |
| Basic EPS | $0.04 | $0.11 | $0.11 | -$0.47 | -$0.56 |
| Diluted EPS | $0.04 | $0.11 | $0.11 | -$0.47 | -$0.56 |
| -Less:Other Special Charges | – | $4.00M | $2.00M | $8.00M | $0.00 |
| -Less:Write Off | – | – | – | $39.00M | – |
| -Gain on Sale Of Business | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $13.34B | $13.56B | $13.22B | $13.36B | $13.36B |
| Total Current Assets | $3.73B | $3.80B | $3.58B | $3.46B | $3.46B |
| Cash and Cash Equivalents & Short-Term Investments | $465.00M | $530.00M | $428.00M | $545.00M | $545.00M |
| -Cash and Cash Equivalents | $465.00M | $530.00M | $428.00M | $545.00M | $545.00M |
| Receivables | $1.06B | $1.15B | $1.15B | $940.00M | $940.00M |
| -Accounts Receivable | $992.00M | $1.08B | $1.08B | $873.00M | $873.00M |
| -Other Receivables | $71.00M | $75.00M | $70.00M | $67.00M | $67.00M |
| Inventory | $1.82B | $1.77B | $1.72B | $1.74B | $1.74B |
| Other Current Assets | $380.00M | $346.00M | $285.00M | $236.00M | $236.00M |
| Total Non-Current Assets | $9.61B | $9.76B | $9.64B | $9.90B | $9.90B |
| Net PPE | $1.44B | $1.41B | $1.40B | $1.41B | $1.41B |
| Goodwill and Other Intangible Assets | $7.83B | $8.05B | $7.95B | $8.19B | $8.19B |
| -Goodwill | $4.80B | $4.85B | $4.72B | $4.78B | $4.78B |
| -Other Intangible Assets | $3.03B | $3.20B | $3.23B | $3.41B | $3.41B |
| Other Non-Current Assets | $347.00M | $304.00M | $295.00M | $304.00M | $304.00M |
| Total Liabilities | $6.71B | $6.97B | $6.72B | $6.81B | $6.81B |
| Total Current Liabilities | $1.79B | $1.85B | $1.66B | $1.60B | $1.60B |
| Payables | $416.00M | $427.00M | $372.00M | $368.00M | $368.00M |
| -Accounts Payable | $416.00M | $427.00M | $372.00M | $368.00M | $368.00M |
| Short-Term Debt and Capital Lease Obligation | $74.00M | $73.00M | $73.00M | $74.00M | $74.00M |
| -Current Debt | $74.00M | $73.00M | $73.00M | $74.00M | $74.00M |
| Current Deferred Liabilities | $443.00M | $450.00M | $400.00M | $416.00M | $416.00M |
| Other Current Liabilities | $854.00M | $902.00M | $817.00M | $533.00M | $533.00M |
| Total Non-Current Liabilities | $4.93B | $5.12B | $5.06B | $5.21B | $5.21B |
| Long Term Debt and Capital Lease Obligation | $3.63B | $3.85B | $3.92B | $3.94B | $3.94B |
| -Long Term Debt | $3.63B | $3.85B | $3.92B | $3.94B | $3.94B |
| Non-Current Deferred Liabilities | $424.00M | $410.00M | $366.00M | $382.00M | $382.00M |
| Other Non-Current Liabilities | $559.00M | $551.00M | $467.00M | $427.00M | $427.00M |
| Total Equity | $6.63B | $6.59B | $6.50B | $6.55B | $6.55B |
| Stockholders' Equity | $6.63B | $6.59B | $6.50B | $6.55B | $6.55B |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $8.90B | $8.88B | $8.86B | $8.87B | $8.87B |
| Retained Earnings | -$2.05B | -$2.07B | -$2.13B | -$2.18B | -$2.18B |
| Gains/Losses Not Affecting Retained Earnings | -$217.00M | -$219.00M | -$233.00M | -$141.00M | -$141.00M |
| -Gross PPE | – | – | – | $2.36B | $2.36B |
| -Accumulated Depreciation | – | – | – | -$952.00M | -$952.00M |
| Employee Benefits | – | – | – | $158.00M | $158.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $216.00M | $277.00M | $13.00M | $560.00M | $108.00M |
| Net cash flow from continuing operations | $216.00M | $277.00M | $13.00M | $560.00M | $108.00M |
| Net Income from Continuing Operations | $18.00M | $54.00M | $57.00M | -$232.00M | -$276.00M |
| Depreciation & Depletion & Amortization | $177.00M | $171.00M | $172.00M | $680.00M | $174.00M |
| Other Non-Cash Items | $29.00M | $8.00M | $26.00M | $8.00M | $56.00M |
| Change in Working Capital | -$31.00M | $24.00M | -$263.00M | $99.00M | $225.00M |
| Net cash flow from investing | -$62.00M | -$110.00M | -$60.00M | -$279.00M | -$64.00M |
| Net Cash Flow from Continuing Investing Activities | -$62.00M | -$110.00M | -$60.00M | -$279.00M | -$64.00M |
| Net PPE Purchase and Sale | -$60.00M | -$33.00M | -$51.00M | -$276.00M | -$62.00M |
| Net Business Purchase and Sale | $0.00 | -$76.00M | $0.00 | $9.00M | $0.00 |
| Net Other Investing Changes | -$2.00M | -$1.00M | -$9.00M | -$12.00M | -$2.00M |
| Financing Cash Flow | -$216.00M | -$74.00M | -$65.00M | -$275.00M | -$18.00M |
| Net Cash Flow from Continuing Financing Activities | -$216.00M | -$74.00M | -$65.00M | -$275.00M | -$18.00M |
| Net Issuance Payments Of Debt | -$215.00M | -$73.00M | -$16.00M | -$563.00M | -$1.00M |
| Net Common Stock Issuance | -$1.00M | -$1.00M | -$34.00M | – | – |
| Net Other Financing Charges | $0.00 | $0.00 | -$15.00M | $288.00M | -$31.00M |
| Ending Cash Balance | $465.00M | $530.00M | $428.00M | $545.00M | $545.00M |
| Net Change in Cash | -$62.00M | $93.00M | -$112.00M | $6.00M | $26.00M |
| Beginning Cash Balance | $530.00M | $428.00M | $545.00M | $468.00M | $505.00M |
| Effect of Exchange Rate Changes | -$3.00M | $9.00M | -$5.00M | $71.00M | $14.00M |
| Free Cash Flow | $156.00M | $244.00M | -$38.00M | $284.00M | $46.00M |
| Deferred Tax | – | – | – | -$134.00M | – |
| -Change in Receivables | – | – | – | -$12.00M | – |
| -Change in Inventory | – | – | – | -$57.00M | – |
| -Change in Payables and Accrued Expense | – | – | – | $147.00M | – |
| -Change in Other Current Assets | – | – | – | $21.00M | – |
No comments yet — be the first to weigh in on ELAN.
Sign in to join the discussion.